Search

Displaying results 2041 - 2050 of 7498 in total
  1. Drug

    Aflibercept

    go.drugbank.com/drugs/DB08885
    ApprovedInvestigational

    [L47915] All five putative N-glycosylation sites on each polypeptide chain predicted by the primary sequence can be occupied with carbohydrates and exhibit some degree of chain heterogeneity, including … the FDA as treatments for retinal diseases; Enzeevi (aflibercept-abzv)[L53053], approved in August 2024, was also approved by the FDA for similar indications.

  2. Drug

    Angiotensin II

    go.drugbank.com/drugs/DB11842
    ApprovedInvestigational

    Shock is the inability to maintain blood flow to vital tissues and the potential resultant organ failure and death within hours, no matter young or o ld. … options for critically ill hypotensive patients who do not adequately respond to currently available therapies.

  3. Drug

    Choline C 11

    go.drugbank.com/drugs/DB09277
    Approved

    [A32041] It was developed by MCPRF and FDA first approved in September 2012.

  4. Drug

    Bepridil

    go.drugbank.com/drugs/DB01244
    ApprovedWithdrawn

    It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). … A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects.

    Categories: Non-Selective Calcium Channel BlockersSynonyms: .-((2-METHYLPROPOXY)METHYL)-N-PHENYL-N-(PHENYLMETHYL)-, 1-(2-(N-BENZYLANILINO)-1-(ISOBUTOXYMETHYL)ETHYL)-PYRROLIDINE
  5. Drug

    Fruquintinib

    go.drugbank.com/drugs/DB11679
    ApprovedInvestigational

    [A262102,A262107] Indeed, oncogenic activation, loss of tumor suppressor function, and hypoxia, usually facilitated by cancer cells, are known to upregulate VEGF. … The first approach can be exemplified by [bevacizumab], a VEGF-A trap antibody.

  6. Drug

    Medifoxamine

    go.drugbank.com/drugs/DB13219
    Approved

    Medifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases of hepatotoxicity

  7. Drug

    Varicella zoster vaccine (live/attenuated)

    go.drugbank.com/drugs/DB10318
    ApprovedInvestigational

    This is a significant improvement over its predecessor, Zostavax, which reduces the risk of shingles by only 51% and the risk of post-herpetic neuralgia by 67% [A31349]. … First approved in May 2006 by the Food and Drug Administration, Zostavax was the first vaccine available for the prevention of shingles.

  8. Drug

    Bosutinib

    go.drugbank.com/drugs/DB06616
    ApprovedInvestigational

    [L48436] On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. … [A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy.

  9. Drug

    Iodoform

    go.drugbank.com/drugs/DB13813
    ApprovedInvestigationalVet approvedWithdrawn

    Iodoform has also been found in dental paste and root canal filling materials in combination with other intracanal medications due to its radiopacity [A32893]. … Due to its antimicrobial properties following topical administration, minimal levels of iodoform may be found in disinfectants and it is more primarily used for veterinary purposes.

  10. Drug

    Pamidronic acid

    go.drugbank.com/drugs/DB00282
    ApprovedInvestigational

    [A203111] Pamidronic acid was granted FDA approval on 31 October 1991.[L13835] … Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid] and [alendronic acid].[A203111] Pamidronic acid was first described in the literature in 1977.